{"id":3861,"date":"2024-11-29T15:21:38","date_gmt":"2024-11-29T12:21:38","guid":{"rendered":"https:\/\/pharmaworlddergi.com\/?p=3861"},"modified":"2024-11-29T15:39:59","modified_gmt":"2024-11-29T12:39:59","slug":"janssen-immun-hastaliklarin-olmadigi-bir-dunya-icin-calisiyor","status":"publish","type":"post","link":"https:\/\/pharmaworlddergi.com\/?p=3861","title":{"rendered":"Janssen, \u0130mm\u00fcn Hastal\u0131klar\u0131n Olmad\u0131\u011f\u0131 Bir D\u00fcnya \u0130\u00e7in \u00c7al\u0131\u015f\u0131yor"},"content":{"rendered":"\n

\u00c7eyrek asra yak\u0131n zamand\u0131r T\u00fcrkiye\u2019de faaliyet g\u00f6steren Janssen T\u00fcrkiye imm\u00fcnoloji alan\u0131nda etki odakl\u0131 \u00e7al\u0131\u015fmalar ger\u00e7ekle\u015ftirmeye devam ediyor. Janssen T\u00fcrkiye \u0130\u015f Birimi Direkt\u00f6r\u00fc Dr. \u00c7a\u011fatay Kele\u015f ve Janssen TURGAN Medikal Direkt\u00f6r\u00fc Dr. \u00d6zg\u00fcr \u015eahincio\u011flu\u2019yla Janssen\u2019in yenilik\u00e7i vizyonuna dair \u00e7al\u0131\u015fmalar\u0131n\u0131, dermatoloji ve bu alandaki endikasyonu psoriasisi konu\u015ftuk.<\/strong><\/p>\n\n\n\n

Janssen T\u00fcrkiye \u0130mm\u00fcnoloji Ekibi\u2019ni biraz tan\u0131yabilir miyiz?<\/strong><\/p>\n\n\n

\n
\"\"<\/figure><\/div>\n\n\n

136 y\u0131ll\u0131k k\u00f6kl\u00fc ge\u00e7mi\u015fiyle d\u00fcnyan\u0131n en b\u00fcy\u00fck sa\u011fl\u0131k hizmetleri \u00fcreticilerinden biri olan Johnson & Johnson\u2019\u0131n ila\u00e7 \u015firketi Janssen olarak, 24 y\u0131ld\u0131r T\u00fcrkiye\u2019de faaliyet g\u00f6steriyoruz. Dermatoloji ve romatoloji genelinde en yayg\u0131n imm\u00fcn arac\u0131l\u0131 ve inflamatuar hastal\u0131klar i\u00e7in tedavi portf\u00f6y\u00fcne sahip oldu\u011fumuz i\u00e7in gurur duyuyoruz. Janssen \u0130mm\u00fcnoloji Ekibi olarak d\u00fcnyan\u0131n her yerinde \u2018do\u011fru hasta i\u00e7in do\u011fru tedavi\u2019 sa\u011flamay\u0131 ama\u00e7layarak ki\u015fiye \u00f6zel yenilik\u00e7i sa\u011fl\u0131k \u00e7\u00f6z\u00fcmleri sunmaya devam ediyoruz.<\/p>\n\n\n\n

\u0130mm\u00fcnoloji ekibimiz, Janssen T\u00fcrkiye liderlik ekibi \u00fcyeleri olan Dr. \u00c7a\u011fatay Kele\u015f ve Dr. \u00d6zg\u00fcr \u015eahincio\u011flu\u2019nun liderli\u011finde yetkin ve deneyimli bir kadrodan olu\u015fuyor.<\/p>\n\n\n\n

Janssen\u2019in imm\u00fcnoloji alan\u0131ndaki vizyonundan s\u00f6z eder misiniz?<\/strong><\/p>\n\n\n\n

Hastalara olan s\u00fcrekli ba\u011fl\u0131l\u0131\u011f\u0131m\u0131z\u0131n bir par\u00e7as\u0131 olarak d\u00fcnya genelinde sa\u011fl\u0131\u011fa katk\u0131 sa\u011flamak i\u00e7in \u00e7al\u0131\u015fmaktay\u0131z. \u0130mm\u00fcn arac\u0131l\u0131 hastal\u0131klara y\u00f6nelik biyolojik ila\u00e7lar geli\u015ftirmek konusunda g\u00fc\u00e7l\u00fc bir ge\u00e7mi\u015fe sahibiz ve imm\u00fcn hastal\u0131klar\u0131n olmad\u0131\u011f\u0131 bir d\u00fcnya yaratma vizyonumuzla beraber, daha fazla insan\u0131n hayat\u0131na dokunmak i\u00e7in ilgilendi\u011fimiz alanlar\u0131 geni\u015fletirken, di\u011fer yandan da heyecan verici, yeni biyoteknolojik \u00fcr\u00fcnler geli\u015ftirmek i\u00e7in \u00e7al\u0131\u015fmalar\u0131m\u0131za devam ediyoruz.<\/p>\n\n\n\n

\u0130mm\u00fcn arac\u0131l\u0131 hastal\u0131klarda kar\u015f\u0131lanmam\u0131\u015f t\u0131bbi ihtiya\u00e7lara y\u00f6nelerek hastalar\u0131n normal bir ya\u015fam s\u00fcrmelerini sa\u011flamak misyonuyla s\u00fcrekli ara\u015ft\u0131rmalar ve i\u015f birlikleri ger\u00e7ekle\u015ftiriyoruz. \u0130mm\u00fcn arac\u0131l\u0131 inflamatuar hastal\u0131klar\u0131n tedavisinde ilklere imza atarak s\u00fcrekli \u00f6nc\u00fc \u00e7\u00f6z\u00fcmler sunmaya \u00e7aba g\u00f6steriyoruz. Ke\u015fifler, biyolojik g\u00f6stergeler (biyobelirte\u00e7), klinik ara\u015ft\u0131rma ve inovasyon alanlar\u0131ndaki s\u00fcrekli \u00e7abalar\u0131m\u0131z ile d\u00fcnyan\u0131n her yerindeki hastalara ve sa\u011fl\u0131k \u00e7al\u0131\u015fanlar\u0131na ya\u015famlar\u0131nda bir d\u00f6n\u00fc\u015f\u00fcm sa\u011flayacak ila\u00e7lar sunuyor, var oldu\u011fumuz alanlarda sekt\u00f6r\u00fcm\u00fcze liderlik etmeye odaklan\u0131yoruz.<\/p>\n\n\n\n

Janssen\u2019in bu alandaki konumundan k\u0131saca s\u00f6z eder misiniz?<\/strong><\/p>\n\n\n\n

Janssen olarak otoimm\u00fcn hastal\u0131klar ile ya\u015fayan hastalar\u0131n ya\u015fam kalitelerini art\u0131rmak ad\u0131na imm\u00fcn hastal\u0131klar\u0131n olmad\u0131\u011f\u0131 bir d\u00fcnya i\u00e7in \u00e7al\u0131\u015f\u0131yoruz. \u0130mm\u00fcnoloji alan\u0131nda yenilik\u00e7i ila\u00e7lar geli\u015ftirmek konusunda \u00f6nemli bir ge\u00e7mi\u015fe sahibiz.\u00a0 Bug\u00fcne kadar geli\u015ftirdi\u011fimiz \u00fcr\u00fcnlerle bu alanda ilklerin firmas\u0131 oldu\u011fumuzu s\u00f6yleyebiliriz. Gelecekte de imm\u00fcnoloji konusunda hastalar\u0131n hayat\u0131na de\u011fer katmaya ve ilklerin firmas\u0131 olarak ilerlemeye devam etmeyi\u00a0hedefliyoruz.<\/p>\n\n\n\n

\u0130mm\u00fcnoloji alan\u0131nda hangi hastal\u0131klara odaklan\u0131yorsunuz?<\/strong><\/p>\n\n\n\n

Janssen olarak imm\u00fcnoloji alan\u0131nda; psoriasis, psoriatik artrit, Crohn hastal\u0131\u011f\u0131, aksiyel spondiloartrit, romatoid artrit ve \u00fclseratif kolit odakland\u0131\u011f\u0131m\u0131z hastal\u0131klar aras\u0131nda yer al\u0131yor.<\/p>\n\n\n\n

29 Ekim D\u00fcnya Sedef Hastalar\u0131 G\u00fcn\u00fc olarak kabul ediliyor. Sedef Hastal\u0131\u011f\u0131 \u00f6zelinde payla\u015fmak istedikleriniz nelerdir?<\/strong><\/p>\n\n\n\n

Sedef hastal\u0131\u011f\u0131 olarak da bilinen psoriasis, d\u00fcnya \u00e7ap\u0131nda 125 milyon ki\u015fiyi etkileyen kronik bir hastal\u0131k.1<\/sup> G\u00fcn\u00fcm\u00fczde h\u00e2l\u00e2 bula\u015f\u0131c\u0131 bir hastal\u0131k gibi alg\u0131lanabiliyor. Ancak psoriasis bula\u015f\u0131c\u0131 de\u011fildir.2<\/sup><\/p>\n\n\n\n

Psoriasise hangi fakt\u00f6rlerin sebep oldu\u011funa ili\u015fkin net bir bulgu bulunmamakla birlikte, psoriasisin ortaya \u00e7\u0131k\u0131\u015f\u0131n\u0131 tetikleyen fakt\u00f6rler ki\u015fiden ki\u015fiye farkl\u0131l\u0131k g\u00f6sterebiliyor. Ba\u011f\u0131\u015f\u0131kl\u0131k sistemi ve genetik sebepler neticesinde ortaya \u00e7\u0131kt\u0131\u011f\u0131 bilinen hastal\u0131k, yeni do\u011fan dahil olmak \u00fczere her ya\u015fta g\u00f6r\u00fclebiliyor. Bu durum da hastal\u0131\u011f\u0131n geli\u015fiminde bir genetik etki s\u00f6z konusu oldu\u011funu g\u00f6steriyor.3,4<\/sup><\/p>\n\n\n\n

Yap\u0131lan ara\u015ft\u0131rmalar, Psoriasisin psikososyal etkilerini ortaya koyuyor. Hastalar\u0131n yaln\u0131zca fiziksel durumlar\u0131na dayanarak de\u011ferlendirilmesi, ya\u015fad\u0131klar\u0131 stres ve duygusal zorluklar\u0131 art\u0131r\u0131yor. Hastalar\u0131n hastal\u0131klar\u0131yla ba\u015fa \u00e7\u0131kma bi\u00e7imlerini olumsuz y\u00f6nde etkileyebiliyor.5<\/sup><\/p>\n\n\n\n

Psikososyal stres, hastal\u0131\u011f\u0131n ba\u015flamas\u0131na ve daha da \u015fiddetlenmesine yol a\u00e7an nedenlerin ba\u015f\u0131nda geliyor. \u00d6zellikle \u015fiddetli seyreden Psoriasis hastalarda strese neden oluyor, ya\u015fan\u0131lan bu stres ise semptomlar\u0131 daha da \u015fiddetli hale getiriyor. Bu durumun hastal\u0131\u011f\u0131n kendi i\u00e7inde k\u0131s\u0131r bir d\u00f6ng\u00fcye d\u00f6n\u00fc\u015ft\u00fcr\u00fcyor.6-7<\/sup><\/p>\n\n\n\n

Ara\u015ft\u0131rmalar, psoriasis hastalar\u0131n\u0131n yar\u0131s\u0131na yak\u0131n bir k\u0131sm\u0131n\u0131n anksiyete ve depresyon duygular\u0131na sahip oldu\u011funu da ortaya koyuyor.8-10<\/sup> Hastalar\u0131n yakla\u015f\u0131k %5-7\u2019si aktif intihar d\u00fc\u015f\u00fcnceleri oldu\u011funu belirtiyor.11<\/sup> Sigaran\u0131n yan\u0131 s\u0131ra sakinle\u015ftirici, uyku ilac\u0131 ve antidepresan kullan\u0131m\u0131 gibi al\u0131\u015fkanl\u0131klar hastan\u0131n ya\u015fam kalitesini olumsuz etkiliyor.12<\/sup> Alkol de hastal\u0131\u011f\u0131n seyrini olumsuz etkileyen fakt\u00f6rler aras\u0131nda yer al\u0131yor. Sedef hastalar\u0131nda alkol t\u00fcketiminin normalden 2-3 kat daha fazla oldu\u011funu g\u00f6r\u00fcl\u00fcyor. Alkol\u00fc a\u015f\u0131r\u0131 \u015fekilde kullanan bireylerde hastal\u0131k daha s\u0131k g\u00f6r\u00fcl\u00fcyor ve daha a\u011f\u0131r ya\u015fan\u0131yor.13,14<\/sup><\/p>\n\n\n\n

Psoriasis hastalar\u0131n\u0131n di\u011fer dermatolojik hastal\u0131klar\u0131 olan bireylere k\u0131yasla daha y\u00fcksek bir stigmatizasyon d\u00fczeyine sahip oldu\u011fu biliniyor. Bu durum, hastalar\u0131n toplumda \u00f6nyarg\u0131larla kar\u015f\u0131 kar\u015f\u0131ya kalmalar\u0131na yol a\u00e7abiliyor.15<\/sup><\/p>\n\n\n\n

Hastalar\u0131n g\u00fcncel tedavi k\u0131lavuzlar\u0131na uygun, ihtiya\u00e7 duyduklar\u0131 yenilik\u00e7i tedavilerle bulu\u015fmalar\u0131n\u0131 sa\u011flayabilmek Janssen olarak \u00f6nceli\u011fimiz. Bu ama\u00e7 do\u011frultusundaki Ar-Ge ve klinik ara\u015ft\u0131rmalar dahil olmak \u00fczere t\u00fcm proje ve \u00e7al\u0131\u015fmalarda yer alarak, alan bilgimizi ve kaynaklar\u0131m\u0131z\u0131 toplum sa\u011fl\u0131\u011f\u0131na katk\u0131da bulunacak \u00e7\u00f6z\u00fcmlere ay\u0131r\u0131yoruz.<\/p>\n\n\n\n

Referanslar:<\/strong><\/strong><\/p>\n\n\n\n

1.Parisi R, Iskandar IYK, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: Systematic analysis and modelling study. BMJ<\/em>. 2020;369:m1590. https:\/\/www.bmj.com\/content\/369\/bmj.m1590<\/a>. Published May 28, 2020. Accessed February 15, 2022.<\/p>\n\n\n\n

2. Lebwohl MG, van de Kerkhof P. Psoriasis. In: Lebwohl MG, Heymann WR, Coulson IH, Murrell DF, eds. Treatment of Skin Disease.<\/em> 6th ed. Philadelphia, PA: Elsevier; 2022:chap 210.<\/p>\n\n\n\n

3. Langley RGB, Krueger GG, Griffiths CEM. Ann Rheum Dis. 2005;64(Suppl II):ii18-ii23.<\/p>\n\n\n\n

 4.Rahman P, Elder JT. Ann Rheum Dis. 2005; Mar;64 Suppl 2:ii37-9<\/p>\n\n\n\n

5. Fortune DG et al. Br J Dermatol. 1997;137(5):755-60.<\/p>\n\n\n\n

6. Devrimci-Ozguven H, et al. JEADV. 2000;14(4):267-71.<\/p>\n\n\n\n

7. Kimball AB et al. Am J Clin Dermatol. 2005;6(6):383-92.<\/p>\n\n\n\n

8. Krueger G et al. Arch Dermatol. 2001;137:280-4. <\/p>\n\n\n\n

9. Weiss SC et al. J Am Acad Dermatol. 2002;47:512-8.<\/p>\n\n\n\n

10. Akay A et al. JEADV. 2002;16:347-52. <\/p>\n\n\n\n

11. Gupta MA, Gupta AK. Br J Dermatol. 1998;139:846-50.<\/p>\n\n\n\n

12.Davidsson S et al. In J Dermatol. 2005;44:378-83. <\/p>\n\n\n\n

13. Farber EM, Nall L. Cutis. 1994;53:21-7.<\/p>\n\n\n\n

14. Wolf R et al. Clin Dermatol. 1999;17:423-30. <\/p>\n\n\n\n

15. Vardy D et al. Br J Dermatol. 2002;147(4):736-42.<\/p>\n","protected":false},"excerpt":{"rendered":"

\u00c7eyrek asra yak\u0131n zamand\u0131r T\u00fcrkiye\u2019de faaliyet g\u00f6steren Janssen T\u00fcrkiye imm\u00fcnoloji alan\u0131nda etki odakl\u0131 \u00e7al\u0131\u015fmalar ger\u00e7ekle\u015ftirmeye devam ediyor. Janssen T\u00fcrkiye \u0130\u015f Birimi Direkt\u00f6r\u00fc Dr. \u00c7a\u011fatay Kele\u015f ve Janssen TURGAN Medikal Direkt\u00f6r\u00fc Dr. \u00d6zg\u00fcr \u015eahincio\u011flu\u2019yla Janssen\u2019in yenilik\u00e7i vizyonuna dair \u00e7al\u0131\u015fmalar\u0131n\u0131, dermatoloji ve bu alandaki endikasyonu psoriasisi konu\u015ftuk.<\/p>\n","protected":false},"author":1,"featured_media":3863,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[48,2],"tags":[],"_links":{"self":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/3861"}],"collection":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3861"}],"version-history":[{"count":5,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/3861\/revisions"}],"predecessor-version":[{"id":3870,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/3861\/revisions\/3870"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/media\/3863"}],"wp:attachment":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3861"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3861"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3861"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}